3 713

Cited 0 times in

Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor.

DC Field Value Language
dc.contributor.author박준철-
dc.contributor.author신성관-
dc.contributor.author윤미진-
dc.contributor.author이상길-
dc.contributor.author이용찬-
dc.contributor.author이재훈-
dc.contributor.author이혁-
dc.contributor.author정현수-
dc.contributor.author최경석-
dc.date.accessioned2014-12-19T16:47:55Z-
dc.date.available2014-12-19T16:47:55Z-
dc.date.issued2012-
dc.identifier.issn1619-7070-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/90214-
dc.description.abstractPURPOSE: Few studies have evaluated metabolic activity by (18)F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC. METHODS: We enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment (18)F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. Stomach(SUVmax) was defined as SUVmax in the stomach, while Total(SUVmax) was defined as the highest SUVmax among all the target lesions. RESULTS: The stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1% of patients). A Total(SUVmax) value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a Total(SUVmax) value <11.5 than in those with a Total(SUVmax) value ≥11.5 (P = 0.023); however, overall survival (OS) was not (P = 0.055). A Stomach(SUVmax) value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach(SUVmax) value <6.0 than in those with a Stomach(SUVmax) value ≥6.0 (P = 0.001 and P = 0.006, respectively). Furthermore, those with a low Total(SUVmax) and those with a low Stomach(SUVmax) showed better chemotherapeutic responses (P = 0.016 and P = 0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower Total(SUVmax) and those with lower Stomach(SUVmax) showed longer median PFS (P = 0.027 and P = 0.005, respectively) and OS (P = 0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach(SUVmax) as an independent predictor of PFS (P = 0.002) and OS (P = 0.038). CONCLUSION: Pretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, Stomach(SUVmax) was the single, most robust factor predicting prognosis.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/diagnostic imaging*-
dc.subject.MESHAdenocarcinoma/metabolism*-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdenocarcinoma/secondary-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18*/pharmacokinetics-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultimodal Imaging-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHPositron-Emission Tomography/methods*-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiopharmaceuticals*/pharmacokinetics-
dc.subject.MESHStomach Neoplasms/diagnostic imaging*-
dc.subject.MESHStomach Neoplasms/metabolism*-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHTomography, X-Ray Computed-
dc.subject.MESHYoung Adult-
dc.titlePredictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJun Chul Park-
dc.contributor.googleauthorJae-Hoon Lee-
dc.contributor.googleauthorKungseok Cheoi-
dc.contributor.googleauthorHyunsoo Chung-
dc.contributor.googleauthorMi Jin Yun-
dc.contributor.googleauthorHyuk Lee-
dc.contributor.googleauthorSung Kwan Shin-
dc.contributor.googleauthorSang Kil Lee-
dc.contributor.googleauthorYong Chan Lee-
dc.identifier.doi10.1007/s00259-012-2116-x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01676-
dc.contributor.localIdA02112-
dc.contributor.localIdA02550-
dc.contributor.localIdA02812-
dc.contributor.localIdA02988-
dc.contributor.localIdA03285-
dc.contributor.localIdA04033-
dc.contributor.localIdA03093-
dc.relation.journalcodeJ00833-
dc.identifier.eissn1619-7089-
dc.identifier.pmid22526958-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00259-012-2116-x-
dc.subject.keywordPretreatment fluorodeoxyglucose uptake-
dc.subject.keywordAdvanced gastric cancer-
dc.subject.keywordMaximal SUV-
dc.subject.keywordChemotherapeutic response-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNamePark, Jun Chul-
dc.contributor.alternativeNameShin, Sung Kwan-
dc.contributor.alternativeNameYun, Mi Jin-
dc.contributor.alternativeNameLee, Sang Kil-
dc.contributor.alternativeNameLee, Yong Chan-
dc.contributor.alternativeNameLee, Jae Hoon-
dc.contributor.alternativeNameLee, Hyuk-
dc.contributor.alternativeNameChung, Hyun Soo-
dc.contributor.alternativeNameCheoi, Kyung Seok-
dc.contributor.affiliatedAuthorPark, Jun Chul-
dc.contributor.affiliatedAuthorShin, Sung Kwan-
dc.contributor.affiliatedAuthorYun, Mi Jin-
dc.contributor.affiliatedAuthorLee, Sang Kil-
dc.contributor.affiliatedAuthorLee, Yong Chan-
dc.contributor.affiliatedAuthorLee, Hyuk-
dc.contributor.affiliatedAuthorCheoi, Kyung Seok-
dc.contributor.affiliatedAuthorLee, Jae Hoon-
dc.citation.volume39-
dc.citation.number7-
dc.citation.startPage1107-
dc.citation.endPage1116-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.39(7) : 1107-1116, 2012-
dc.identifier.rimsid34073-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.